化感作用相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
121	합성 장뇌에 의한 원치 않는 감각 효과의 억제	KR1020127028126	2011-03-28	KR1020130029067A	2013-03-21	코발,거드; 고고바,마리아; 폴루르,프라사드; 맥키니,다이애나
무연 담배 제품(10, 100) 또는 의료용 니코틴 제품은 니코틴, 및 풍미가 첨가되지 않은 기름성 운반체에 용해된 장뇌를 포함한다. 바람직하게는, 장뇌가 약 600~1300 ppm의 농도로 존재한다. 또한, 그와 같은 제품의 제조 방법들이 개시된다.
122	Inhibition of HIV infection through chemoprophyalxis	US14679887	2015-04-06	US09579333B2	2017-02-28	Walid Heneine; Thomas M. Folks; Robert Janssen; Ronald A. Otten; Jose Gerardo Garcia Lerma
A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.
123	INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR	US14591485	2015-01-07	US20150126561A1	2015-05-07	Gerd Kobal; Prasad Polur; Maria Gogova; Diana McKinney
A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.
124	Action pole for electrochemical gas sensor, and manufacturing method of the same	JP2012286462	2012-12-28	JP2014130018A	2014-07-10	YAMAGUCHI NAOTO; NIWA OSAMU; KAMATA TOMOYUKI; KATO MASARU
PROBLEM TO BE SOLVED: To provide an action pole on which a nano platinum particle containing carbon layer suitable for an electrochemical gas sensor capable of suppressing sensitivity to hydrogen is formed.SOLUTION: A nano platinum particle containing carbon layer 3 is formed on one surface of a water-repellent ventilation film 1 via a silicon layer 2.
125	Inhibition of undesired sensory effects by the compound camphor	US13071889	2011-03-25	US08952038B2	2015-02-10	Gerd Kobal; Prasad Polur; Maria Gogova; Diana McKinney
A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.
126	INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR	US13071889	2011-03-25	US20120052021A1	2012-03-01	Gerd Kobal; Prasad Babu Deenadayalan Polur; Maria Gogova; Diana McKinney
A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.
127	EFFERVESCENT WHITENING DENTIFRICE HAVING SENSORY SIGNAL BASED ON THE RELEASE OR OXYGEN	PCT/US0116652	2001-05-23	WO0189463A3	2002-05-30	HOIC DIEGO A; VISCIO DAVID B; MASTERS JAMES G
An effervescent two component whitening dentifrice composition is disclosed which comprises a first component containing a peroxide compound such as hydrogen peroxide and a second dentifrice component containing a mixture of iron and copper salts such as FeSO4 and CaSO4, which when the two components are combined and mixed upon application to the teeth provides an effervescent sensory signal concomitant with whitening of the teeth.
128	Pixelated detectors with depth of interaction sensitivity	US11720761	2005-12-05	US07932497B2	2011-04-26	Thomas L. Laurence; Steven E. Cooke
A radiation detector (10, 10′) includes scintillator pixels (30) that each have a radiation-receiving end, a light-output end, and reflective sides extending therebetween. The reflective sides have a reflection characteristic (40, 40′, 41, 44) varying between the radiation-receiving end and the light-output end such that a lateral spread of light emanating from the light-output ends of the scintillator pixels responsive to a scintillation event generated in one of the scintillator pixels depends upon a depth of the scintillation event in the scintillator pixel. A plurality of light detectors (46) optically communicate with the light-output ends of the scintillator pixels to receive light produced by scintillation events.
129	INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR	PCT/IB2011000994	2011-03-28	WO2011117735A8	2011-11-10	KOBAL GERD; GOGOVA MARIA; POLUR PRASAD; MCKINNEY DIANA
A smokeless tobacco product (10, 100) or medicinal nicotine product comprises nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 to about 1300 ppm. Also disclosed are methods of making such products.
130	システムレベル相互作用モデルを用いる神経系の刺激及び感知のためのシステム、方法、及び視覚化ツール	JP2016531002	2014-11-11	JP6352416B2	2018-07-04	モフィットマイケルエイ; カルブナルラファエル

131	システムレベル相互作用モデルを用いる神経系の刺激及び感知のためのシステム、方法、及び視覚化ツール	JP2016531002	2014-11-11	JP2017500911A	2017-01-12	マイケルエイモフィット; ラファエルカルブナル
コンピュータ実施式システム及び方法は、神経要素ベースで刺激に応答する患者の患者特有モデルを生成し、ターゲット神経変調部位のユーザ入力を受信し、かつ患者特有モデルに基づいて、刺激部位を含むどの刺激パラダイム及び設定値がターゲット神経変調をもたらすと考えられるかを決定し、ここで刺激部位は、必ずしも得られる神経変調部位と同じではない。システムは、ターゲット神経変調をもたらすと考えられる刺激部位の視覚表現を出力する。システムは、システム状態及び/又は患者状態をモニタし、かつ状態に基づいてどの刺激プログラムを実施するかを動的に変更する。
132	藉使用一種受GST活化抗癌化合物之療法以使對另一抗癌療法敏感化及/或改善另一抗癌療法之副作用 SENSITIZATION TO ANOTHER ANTICANCER THERAPY AND/OR AMELIORATION OF A SIDE EFFECT OF ANOTHER ANTICANCER THERAPY BY TREATMENT WITH A GST-ACTIVATED ANTICANCER COMPOUND	TW094115086	2005-05-10	TW200538149A	2005-12-01	蓋爾L 布朗 BROWN, GAIL L.; 詹姆士G 凱克 KECK, JAMES G.; 米歇爾M 維克 WICK, MICHAEL M.
本發明係關於一種GST活化抗癌化合物用於製造使哺乳動物，尤其是人類，對另一抗癌療法(亦即一種並非以GST活化抗癌化合物治療的抗癌療法－包括化學療法、分子標靶療法、生物療法、和放射療法，每一者以單一療法使用，或兩種或多於兩種合併使用)敏感化，或用於改善另一抗癌療法在哺乳動物，尤其是人類，之副作用的用途。一種用於上述用途的包含GST活化抗癌化合物之組合物。一種使哺乳動物，尤其是人類，對另一抗癌療法敏感化的方法，其包括施用敏感化有效量之一種GST活化抗癌化合物。一種改善另一抗癌療法在哺乳動物，尤其是人類，之副作用的方法，其包括施用改善有效量之一種GST活化抗癌化合物。該GST活化抗癌化合物較好是一種美國專利案第5,556,942號的化合物，更好是坎、佛司福醯胺(canfosfamide)，尤其是呈鹽酸鹽。094115086-p01.bmp
133	INHIBITION OF C. DIFFICILE INFECTIONS BY INDIGESTIBLE OLIGOSACCHARIDES	EP96912568.0	1996-04-04	EP0820292A1	1998-01-28	GARLEB, Keith Allen; WOLF, Brian Warren; MEULBROEK, Jonathan Allan; WHEELER, Keith Brian; CAMPBELL, Shelia Martinson; WALTON, Joseph Edward
The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection. An oral rehydration solution containing such indigestible oligosaccharides also provides fluid and electrolyte replacement.
134	PAIRED STIMULATION PULSES BASED ON SENSED COMPOUND ACTION POTENTIAL	US14530372	2014-10-31	US20160121124A1	2016-05-05	Lisa M. Johanek; Nathan A. Torgerson; Louis Vera-Portocarrero
In some examples, a method may include delivering an electrical stimulation therapy to a patient, the electrical stimulation therapy comprising a first electrical stimulation pulse delivered to the patient via a first electrode and a second electrical stimulation pulse delivered to the patient via a second electrode, wherein the first electrical stimulation pulse and second electrical stimulation pulse are delivered as paired pulses with respect to each other and a combination of the first electrical stimulation pulse and the second electrical stimulation pulse evoke a compound action potential within the patient; sensing the compound action potential evoked by the combination of the first electrical stimulation pulse and the second electrical stimulation pulse; and adjusting one or more parameters of the electrical stimulation therapy based on the sensed compound action potential
135	NOVEL HCV CULTURE SYSTEMS AND DIRECT-ACTING ANTIVIRAL SENSITIVITY	US15025833	2014-10-21	US20160244729A1	2016-08-25	Yiping Li; Santseharay Ramirez Almeida; Daryl Grant Humes; Judith M. Gottwein; Jens Bukh
The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.
136	NOVEL HCV CULTURE SYSTEMS AND DIRECT-ACTING ANTIVIRAL SENSITIVITY	PCT/DK2014050343	2014-10-21	WO2015058772A3	2015-06-18	LI YIPING; ALMEIDA SANTSEHARAY RAMIREZ; HUMES DARYL GRANT; GOTTWEIN JUDITH M; BUKH JENS
The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.
137	分割放射線療法および化学療法と併用するフルオロカーボンの水中エマルジョン、およびそれを含む感作用組成物	JP2020114490	2020-07-01	JP2020172513A	2020-10-22	アンガー, エヴァン, シー.
【課題】化学療法薬の反復投与および/または放射線療法と併用する、酸素療法の提供。【解決手段】フルオロカーボンの水中エマルジョンであって、エマルジョンは分割放射線療法および化学療法と同時に併用され、フルオロカーボンはペルフルオロペンタンとペルフルオロヘキサンから選択されるペルフルオロカーボンであり、フルオロカーボンの濃度はエマルジョンにおいて約1〜約5%weight/volumeであり、前記エマルジョンはスクロースを含む粘性修飾因子およびPEGテロマーBを含む、エマルジョン。【選択図】図1A
138	分割放射線療法および化学療法と併用するフルオロカーボンの水中エマルジョン、およびそれを含む感作用組成物	JP2020114490	2020-07-01	JP6953591B2	2021-10-27	アンガー, エヴァン, シー.

139	Implantable pressure transducer system optimized for reduced thrombosis effect	US11111691	2005-04-21	US08303511B2	2012-11-06	Neal L. Eigler; Brian M. Mann; James S. Whiting; Werner Hafelfinger
This invention relates generally to systems and methods for optimizing the performance and minimizing complications related to implanted sensors, such as pressure sensors, for the purposes of detecting, diagnosing and treating cardiovascular disease in a medical patient. Systems and methods for anchoring implanted sensors to various body structures are also provided.
140	Implantable pressure transducer system optimized for reduced thrombosis effect	US11111691	2005-04-21	US20050288596A1	2005-12-29	Neal Eigler; Brian Mann; James Whiting; Werner Hafelfinger
This invention relates generally to systems and methods for optimizing the performance and minimizing complications related to implanted sensors, such as pressure sensors, for the purposes of detecting, diagnosing and treating cardiovascular disease in a medical patient. Systems and methods for anchoring implanted sensors to various body structures are also provided.

2 3 4 5 6 7 8 9 10 11

IPRDB

热门服务

关于我们

友情链接

联系方式